U.S. markets open in 3 hours 50 minutes
  • S&P Futures

    3,459.25
    +10.00 (+0.29%)
     
  • Dow Futures

    28,375.00
    +107.00 (+0.38%)
     
  • Nasdaq Futures

    11,665.00
    +15.25 (+0.13%)
     
  • Russell 2000 Futures

    1,638.50
    +7.90 (+0.48%)
     
  • Crude Oil

    40.74
    +0.10 (+0.25%)
     
  • Gold

    1,913.50
    +8.90 (+0.47%)
     
  • Silver

    24.94
    +0.24 (+0.96%)
     
  • EUR/USD

    1.1854
    +0.0028 (+0.24%)
     
  • 10-Yr Bond

    0.8480
    0.0000 (0.00%)
     
  • Vix

    27.87
    -0.78 (-2.72%)
     
  • GBP/USD

    1.3101
    +0.0021 (+0.16%)
     
  • USD/JPY

    104.5730
    -0.2670 (-0.25%)
     
  • BTC-USD

    12,966.99
    +0.25 (+0.00%)
     
  • CMC Crypto 200

    261.66
    +5.56 (+2.17%)
     
  • FTSE 100

    5,853.55
    +67.90 (+1.17%)
     
  • Nikkei 225

    23,516.59
    +42.32 (+0.18%)
     

Are Hologic, Inc. (NASDAQ:HOLX) Investors Paying Above The Intrinsic Value?

Simply Wall St
·6 mins read

In this article we are going to estimate the intrinsic value of Hologic, Inc. (NASDAQ:HOLX) by taking the forecast future cash flows of the company and discounting them back to today's value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.

See our latest analysis for Hologic

The calculation

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:

10-year free cash flow (FCF) estimate

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF ($, Millions)

US$1.23b

US$1.49b

US$942.0m

US$871.3m

US$831.4m

US$810.2m

US$801.2m

US$800.3m

US$805.0m

US$813.6m

Growth Rate Estimate Source

Analyst x3

Analyst x1

Analyst x1

Est @ -7.5%

Est @ -4.59%

Est @ -2.54%

Est @ -1.11%

Est @ -0.11%

Est @ 0.59%

Est @ 1.08%

Present Value ($, Millions) Discounted @ 8.1%

US$1.1k

US$1.3k

US$745

US$637

US$562

US$506

US$463

US$428

US$398

US$372

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$6.5b

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.2%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 8.1%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = US$814m× (1 + 2.2%) ÷ (8.1%– 2.2%) = US$14b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$14b÷ ( 1 + 8.1%)10= US$6.4b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$13b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of US$62.0, the company appears slightly overvalued at the time of writing. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

Important assumptions

We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Hologic as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 8.1%, which is based on a levered beta of 0.986. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Whilst important, the DCF calculation is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. What is the reason for the share price exceeding the intrinsic value? For Hologic, there are three relevant factors you should look at:

  1. Risks: Case in point, we've spotted 3 warning signs for Hologic you should be aware of.

  2. Future Earnings: How does HOLX's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.